{
  "success": true,
  "fetched_at": "2026-02-01T03:26:55.187011",
  "ticker": "4502",
  "ticker_full": "4502.T",
  "company_name": "TAKEDA PHARMACEUTICAL CO LTD",
  "company_info": {
    "name_en": "TAKEDA PHARMACEUTICAL CO LTD",
    "long_name": "Takeda Pharmaceutical Company Limited",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "website": "https://www.takeda.com",
    "employees": 47455,
    "country": "Japan",
    "city": "Tokyo",
    "address": "1-1, Nihonbashi-Honcho 2-chome",
    "description": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan."
  },
  "price_trend": {
    "ma_5": {
      "ma_value": 5139.2,
      "deviation": 2.0,
      "trend": "up"
    },
    "ma_25": {
      "ma_value": 5020.08,
      "deviation": 4.42,
      "trend": "up"
    },
    "ma_75": {
      "ma_value": 4583.75,
      "deviation": 14.36,
      "trend": "up"
    },
    "ma_200": {
      "ma_value": 4366.47,
      "deviation": 20.05,
      "trend": "up"
    }
  },
  "financials": {
    "years": [
      {
        "year": 2025,
        "revenue": 4581551000000.0,
        "revenue_fmt": "¥4.6T",
        "gross_profit": 3001334000000.0,
        "gross_profit_fmt": "¥3.0T",
        "operating_income": 486061000000.0,
        "operating_income_fmt": "¥4861億",
        "ebit": 312395000000.0,
        "ebit_fmt": "¥3124億",
        "net_income": 107928000000.0,
        "net_income_fmt": "¥1079億",
        "eps": 67.23,
        "operating_margin": 10.61,
        "total_assets": 14248344000000.0,
        "total_assets_fmt": "¥14.2T",
        "total_equity": 6935084000000.0,
        "total_equity_fmt": "¥6.9T",
        "total_debt": 4515265000000.0,
        "total_debt_fmt": "¥4.5T",
        "total_cash": 385113000000.0,
        "total_cash_fmt": "¥3851億",
        "equity_ratio": 48.67,
        "de_ratio": 0.65,
        "current_ratio": 1.01,
        "operating_cf": 1057182000000.0,
        "operating_cf_fmt": "¥1.1T",
        "investing_cf": -367060000000.0,
        "investing_cf_fmt": "-¥3671億",
        "financing_cf": -751425000000.0,
        "financing_cf_fmt": "-¥7514億",
        "free_cf": 677557000000.0,
        "free_cf_fmt": "¥6776億",
        "net_margin": 2.36,
        "roe": 1.56,
        "roa": 0.76
      },
      {
        "year": 2024,
        "revenue": 4263762000000.0,
        "revenue_fmt": "¥4.3T",
        "gross_profit": 2837084000000.0,
        "gross_profit_fmt": "¥2.8T",
        "operating_income": 366165000000.0,
        "operating_income_fmt": "¥3662億",
        "ebit": 172326000000.0,
        "ebit_fmt": "¥1723億",
        "net_income": 144067000000.0,
        "net_income_fmt": "¥1441億",
        "eps": 91.16,
        "operating_margin": 8.59,
        "total_assets": 15108792000000.0,
        "total_assets_fmt": "¥15.1T",
        "total_equity": 7273264000000.0,
        "total_equity_fmt": "¥7.3T",
        "total_debt": 4843752000000.0,
        "total_debt_fmt": "¥4.8T",
        "total_cash": 457800000000.0,
        "total_cash_fmt": "¥4578億",
        "equity_ratio": 48.14,
        "de_ratio": 0.67,
        "current_ratio": 1.11,
        "operating_cf": 716344000000.0,
        "operating_cf_fmt": "¥7163億",
        "investing_cf": -463862000000.0,
        "investing_cf_fmt": "-¥4639億",
        "financing_cf": -354416000000.0,
        "financing_cf_fmt": "-¥3544億",
        "free_cf": 235614000000.0,
        "free_cf_fmt": "¥2356億",
        "net_margin": 3.38,
        "roe": 1.98,
        "roa": 0.95
      },
      {
        "year": 2023,
        "revenue": 4027478000000.0,
        "revenue_fmt": "¥4.0T",
        "gross_profit": 2783406000000.0,
        "gross_profit_fmt": "¥2.8T",
        "operating_income": 587812000000.0,
        "operating_income_fmt": "¥5878億",
        "ebit": 492063000000.0,
        "ebit_fmt": "¥4921億",
        "net_income": 317017000000.0,
        "net_income_fmt": "¥3170億",
        "eps": 201.94,
        "operating_margin": 14.6,
        "total_assets": 13957750000000.0,
        "total_assets_fmt": "¥14.0T",
        "total_equity": 6354122000000.0,
        "total_equity_fmt": "¥6.4T",
        "total_debt": 4382341000000.0,
        "total_debt_fmt": "¥4.4T",
        "total_cash": 533530000000.0,
        "total_cash_fmt": "¥5335億",
        "equity_ratio": 45.52,
        "de_ratio": 0.69,
        "current_ratio": 0.97,
        "operating_cf": 977156000000.0,
        "operating_cf_fmt": "¥9772億",
        "investing_cf": -607102000000.0,
        "investing_cf_fmt": "-¥6071億",
        "financing_cf": -709148000000.0,
        "financing_cf_fmt": "-¥7091億",
        "free_cf": 343467000000.0,
        "free_cf_fmt": "¥3435億",
        "net_margin": 7.87,
        "roe": 4.99,
        "roa": 2.27
      },
      {
        "year": 2022,
        "revenue": 3569006000000.0,
        "revenue_fmt": "¥3.6T",
        "gross_profit": 2462160000000.0,
        "gross_profit_fmt": "¥2.5T",
        "operating_income": 546043000000.0,
        "operating_income_fmt": "¥5460億",
        "ebit": 425003000000.0,
        "ebit_fmt": "¥4250億",
        "net_income": 230059000000.0,
        "net_income_fmt": "¥2301億",
        "eps": 145.87,
        "operating_margin": 15.3,
        "total_assets": 13178018000000.0,
        "total_assets_fmt": "¥13.2T",
        "total_equity": 5683019000000.0,
        "total_equity_fmt": "¥5.7T",
        "total_debt": 4345411000000.0,
        "total_debt_fmt": "¥4.3T",
        "total_cash": 849695000000.0,
        "total_cash_fmt": "¥8497億",
        "equity_ratio": 43.12,
        "de_ratio": 0.76,
        "current_ratio": 1.21,
        "operating_cf": 1123105000000.0,
        "operating_cf_fmt": "¥1.1T",
        "investing_cf": -198125000000.0,
        "investing_cf_fmt": "-¥1981億",
        "financing_cf": -1070265000000.0,
        "financing_cf_fmt": "-¥1.1T",
        "free_cf": 937068000000.0,
        "free_cf_fmt": "¥9371億",
        "net_margin": 6.45,
        "roe": 4.05,
        "roa": 1.75
      }
    ],
    "has_data": true
  },
  "dividends": {
    "history": [
      {
        "year": 2021,
        "amount": 180.0
      },
      {
        "year": 2022,
        "amount": 180.0
      },
      {
        "year": 2023,
        "amount": 184.0
      },
      {
        "year": 2024,
        "amount": 192.0
      },
      {
        "year": 2025,
        "amount": 198.0
      }
    ],
    "latest": 100.0,
    "has_data": true
  }
}